merging evidence from experimental and clinical research indicates that endoplasmic reticulum (ER) stress is involved in cardiovascular diseases such as cardiac hypertrophy, heart failure, atherosclerosis, and ischemic heart disease. [1] [2] [3] Although the clinical management of hypertension has advanced substantially, cardiovascular disease still constitutes a major and increasing health burden worldwide. Although treatments for hypertension have progressed, the development of novel therapies for patients with vascular complications and cardiac damage in hypertension remains a major research goal. These thoughts are supported by the observation that impaired macro-and microcirculatory heart function predicts poor outcome for patients with cardiovascular disease.
are important questions that have remained unanswered. Therefore, the aim of the present study was to determine the role of ER stress in vascular endothelial dysfunction and cardiac damage in angiotensin II (ang II)-induced hypertension model.
Materials and Methods
An extensive description of materials and methods can be found in the online-only Data Supplement. A brief summary is given below.
General Protocol in Mice
One hundred mice (C57BL/6J, 8-week-old males) were purchased from Jackson Laboratories (Bar Harbor, ME).
Cardiac Fibrosis
Transverse sections of left ventricle were stained with the collagenspecific stain Sirius red (Sigma-Aldrich, St. Louis, MO).
Vascular Reactivity

In Vivo Experiments
Aorta and mesenteric resistance arteries (MRA) were mounted in a small vessel dual-chamber myograph for measurement of isometric tension. 12, 13 After preconstriction with phenylephrine (10 −4 mol/L) and steady maximal contraction, cumulative concentration response curves were obtained for acetylcholine (1×10 −8 to 3×10 −5 mol/L) and sodium nitroprusside (1×10 −8 to 3×10 −5 mol/L).
Hypertrophy
Hearts were harvested and then atrium and all epicardial fat were removed. Cardiac hypertrophy was calculated using heart weight/ body weight ratios.
Active Transforming Growth Factor-β1 Level
Active transforming growth factor-β1 (TGF-β1) level was measured in heart, aorta, and MRA tissue lysates using TGF-β1 immunoassay (Quantikine, R&D systems, Minneapolis, MN) as previously described.
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Western Blot Analysis
Western blot analysis for endothelial NO synthase (eNOS), eukaryotic translation initiation factor 2α, TGF-β1, GRP78 (1:1000 dilution; Cell Signaling Technology, Inc), collagen I, P-Smad2/3, and Smad1/2/3 (1:250 dilution; Santa Cruz Biotechnology, Inc) was performed in lysates of aorta, MRA, and heart as previously described.
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Immunofluorescence
Immunostaining was performed for C/EBP homologous protein (CHOP) in paraffin sections of aorta and MRA using specific antibodies, anti-CHOP (1:200, Santa Cruz Biotechnology, Inc).
Immunohistochemistry
Aorta, MRA, and hearts were fixed in 4% paraformaldehyde followed by zinc-saturated formalin for immunohistochemical studies.
Immunostaining was performed as previously described.
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Terminal Deoxynucleotidyl Transferase dUTP NickEnd Labeling Assay
Four-micrometer paraffin sections from heart were mounted using Vectashield with 4',6-diamidino-2-phenylindole (Vector Laboratories, Inc). The images were captured using a deconvolution fluorescent scope.
Reverse Transcription Polymerase Chain Reaction Real-Time Assay
CHOP, ATF4, ATF6, and TGF-β1 mRNA levels were determined in heart, aorta, and MRA from all groups, whereas nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 (Nox1), Nox2, and Nox4 mRNA levels were studied only in vessels.
Nitrite Levels
The amount of nitrites, the end product of NO metabolism, was measured in plasma samples by the Griess reaction.
Results
General Parameters
Mice infused with ang II showed a significant increase in Figure 1A ). Body weight was similar in all groups of mice ( Figure 1B ). Blood glucose level was higher in hypertensive (178.5±1.6 mg/dL) compared with Sham mice (131±3.5 mg/dL), and was reduced by ER stress inhibitors ( Figure 1C ). Cardiac hypertrophy was observed in mice infused with ang II compared with Sham and mice infused with ang II treated with ER stress inhibitors ( Figure 1D ).
Cardiac Fibrosis
Chronic ang II infusion induces cardiac fibrosis associated with increased active caspase-3, cardiomyocyte size, and apoptotic cells (Figure 2A and 2C-2E). In addition, collagen type I expression and mRNA levels of ATF4, CHOP, and ATF6 were also increased ( Figure 2B , 2G, and 2H; Figure IIA in the online-only Data Supplement). All these parameters were significantly reduced with ER stress inhibitors ( Figure 2A -2E, 2G, and 2H; Figure IIA in the online-only Data Supplement). The mRNA level of TGF-β1 in heart was similar in all groups ( Figure 2I ) whereas active TGF-β1 level, and total and phosphorylated Smad2/3 were increased in hearts from hypertensive mice compared with Sham and hypertensive mice treated with ER stress inhibitors ( Figure 2F and 2J).
ER Stress and TGF-β1 in Aorta and MRA
Ang II-induced hypertension increased ATF4, CHOP mRNA levels, and phosphorylated eukaryotic translation initiation factor 2α levels, which were reduced with ER stress inhibition in aorta and MRA ( Figure 3A -3C, 3I-3K; Figure IIB and IIC in the online-only Data Supplement). We observed a different pattern in mRNA level, and total and active form of TGF-β1 between aorta and MRA. Thus, TGF-β1 mRNA and protein levels, its active form, and phosphorylated Smad2/3 were augmented in aorta from hypertensive mice and reduced with ER stress inhibitors ( Figure 3D -3H), whereas no changes were observed in MRA in all groups of mice ( Figure 3L -3P).
ER Stress and Vascular Reactivity in Hypertension
To determine the role of ER stress in vascular endothelial dysfunction in hypertension, we examined endotheliumdependent relaxation (EDR) and endothelium-independent The inhibition of eNOS with L-NAME reduced EDR in hypertensive mice ( Figure 4C and 4K) and Sham mice ( Figure IB and IE in the online-only Data Supplement). Ang II-induced hypertension reduced eNOS phosphorylation in aorta and MRA, which was restored after ER stress inhibition. In Sham mice treated with Tudca and PBA, we did not observe any effect on eNOS phosphorylation in aorta and MRA. Total eNOS expression was similar in all groups of mice ( Figure  4E and 4M). In addition, nitrite levels were reduced in plasma from hypertensive mice and restored after ER stress inhibition ( Figure IID in the online-only Data Supplement).
To further elucidate the mechanism of vascular endothelial dysfunction in hypertension related to ER stress, we studied the involvement of Nox and TGF-β1 pathways. Our data indicated that inhibition of Nox with apocynin slightly enhanced EDR in aorta but completely restored EDR in MRA, whereas TGF-β1 receptor antagonist significantly enhanced EDR in the aorta but no effect was observed in MRA ( Figure 4D and 4L). Ang II-induced hypertension increased Nox activity in both arteries, Nox1 and Nox4 mRNA levels in aorta and MRA, respectively, which were reduced after ER stress inhibition ( Figure 4F-4H, 4N-4P ). These results were associated with augmented active TGF-β1 levels in aorta from hypertensive mice, which were reduced after ER stress inhibition ( Figure 3E and 3G ). In MRA, we did not see an increase in active TGF-β1 in all groups of mice ( Figure 3M and 3O).
Oxidative Stress, TGF-β1, and Vascular Reactivity
To further determine the relationship between ER stress and vascular dysfunction, we performed in vitro studies by incubating isolated aorta and MRA from control mice with ER stress inducer (tunicamycin) for 1 hour. The results showed that tunicamycin significantly reduced EDR in aorta and MRA, which was prevented when aorta was pretreated with Tudca or TGF-β1 pathway inhibition and when MRA was pretreated with Tudca or apocynin ( Figure III in the online-only Data Supplement).
In vivo studies showed that tunicamycin injection with and without TGF-β1 pathway inhibition did not increase systolic blood pressure ( Figure 5A ). Tunicamycin injection increased ER stress marker expression in aorta and MRA, which was reduced only in aorta with TGF-β1 receptor antagonist (SB431542) and 1D11 neutralizing TGF-β1 antibodies ( Figure 5B -5E, 5G, and 5H). The mRNA level of TGF-β1 was augmented in aorta and reduced with 1D11 and SB431542 ( Figure 5F ), but no change was observed in MRA ( Figure 5I ). Mice injected with tunicamycin showed an attenuated EDR in aorta and MRA ( Figure 6A and 6D) . The in vivo inhibition of TGF-β1 pathway restored EDR in aorta, whereas only a minor improvement in EDR was observed in MRA ( Figure 6A and  6D ). In addition, the incubation of MRA with apocynin C, and E) . Activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) mRNA levels, normalized to 18S ribosomal RNA (rRNA), in heart (G and H). Western blot analysis and quantitative data for collagen I, T-Smad1/2/3, and P-Smad2/3 in heart (B and F) from all groups, n=5. Transforming growth factor-β1 (TGF-β1) mRNA levels, normalized to 18S rRNA, in heart (I) in all groups, n=6. Active TGF-β1 levels in heart (J) in all groups, n=5. *P<0.05 for HT vs control, control+PBA, control+Tudca, HT+PBA, and HT+Tudca. HT indicates hypertension; PBA, 4-phenylbutyric acid; Tudca, taurine-conjugated ursodeoxycholic acid. Figure 3. A, B, I , and J, Activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) mRNA levels, normalized to 18S ribosomal RNA (rRNA), in aorta and mesenteric resistance arteries (MRA) in all groups of mice, n=6. C and K, Western blot analysis and quantitative data for eukaryotic translation initiation factor 2α (eIF2α), P-eIF2α in aorta and MRA in all groups of mice, n=5. D and L, Transforming growth factor-β1 (TGF-β1) mRNA levels, normalized to 18S rRNA, in aorta and MRA in all groups of mice, n=6. E, M, G, and O, Active TGF-β1 levels in aorta and MRA in all groups of mice, n=4. F, H, N, and P, Western blot analysis and quantitative data for TGF-β1, T-Smad1/2/3, and P-Smad2/3 in aorta and MRA in all groups, n=5.*P<0.05 for HT vs control, control+PBA, control+Tudca, HT+PBA, and HT+Tudca. HT indicates hypertension; PBA, 4-phenylbutyric acid; Tudca, taurine-conjugated ursodeoxycholic acid. Figure 4. A, B, C, I , J, and K, Endothelium-dependent and independent relaxation in response to acetylcholine (Ach) and single-nucleotide polymorphism (SNP), respectively, in aorta and mesenteric resistance arteries (MRA) with and without L-NAME in all groups, n=10. E and M, Western blot analysis and quantitative data for P-endothelial NO synthase (eNOS), T-eNOS, and β-actin in aorta and MRA in all groups, n=5. D and L, Endothelium-dependent relaxation in response to ACh with and without apocynin (Apo) and SB431542 in aorta and MRA in all groups of mice, n=5. F and N, Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in aorta and MRA in all groups of mice, n=5. G, H, O, and P, NADPH oxidase 1 (Nox1) and Nox4 mRNA levels, normalized to 18S ribosomal RNA (rRNA), in aorta and MRA from all groups, n=6. *P<0.05 for HT vs control, control+PBA, control+Tudca, HT+PBA, and HT+Tudca. HT indicates hypertension; PBA, 4-phenylbutyric acid; Tudca, taurine-conjugated ursodeoxycholic acid.
completely restored EDR, whereas no effect was observed in aorta isolated from tunicamycin-injected mice treated with and without SB431542 or 1D11 ( Figure 6B , 6C, 6E, and 6F). The L-NAME completely blocked the EDR in aorta whereas partially in MRA from control mice treated with tunicamycin with and without TGF-β1 pathway inhibition ( Figure 6B , 6C, 6E, and 6F).
In other experiments, our results showed that mice injected with tunicamycin with and without Tudca did not affect systolic blood pressure or induce cardiac hypertrophy ( Figure  IVA and IVB in the online-only Data Supplement). However, tunicamycin injection moderately induced cardiac fibrosis that was reduced after ER stress inhibition ( Figure IVC in the online-only Data Supplement). The size of cardiomyocytes did not change between groups (data not shown). Nox activity was increased in aorta and MRA from mice injected with tunicamycin, and treatment with Tudca restored the activity ( Figure IVD and IVE in the online-only Data Supplement). The EDR was impaired in aorta and MRA from mice injected with tunicamycin, which was restored after ER stress inhibition ( Figure VA and VD in the online-only Data Supplement). To determine the mechanism how tunicamycin impairs vascular function, aorta and MRA from mice injected with tunicamycin were incubated with apocynin. The data showed that EDR was restored in MRA, whereas no effect was observed in aorta ( Figure VB and VE in the online-only Data Supplement). The L-NAME completely blocked EDR in aorta whereas partially in MRA from control mice injected with tunicamycin with or without Tudca ( Figure VC and VF in the online-only Data Supplement).
To demonstrate the induction of ER stress in vascular endothelial cells, we performed immunostaining, and data indicate the presence of ER stress marker (CHOP) in endothelial cells of aorta and MRA from mice injected with tunicamycin. The induction of CHOP in vascular endothelial cells was blunted in mice injected with tunicamycin and treated with Tudca ( Figure VIA and VIB in the online-only Data Supplement).
Discussion
Our study demonstrated that ER stress is an important factor in macro-and microvascular pathology and cardiac damage in hypertension. Such evidence first came from in vivo experiments in which hypertensive mice treated with ER stress inhibitors had reduced arterial blood pressure and improved EDR and cardiac damage. We further demonstrated that ER stress inhibition in hypertension differentially improves macrovascular endothelial function by TGF-β1-dependent D, E, F, G, H, and I , Activating transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), and transforming growth factor-β1 (TGF-β1) mRNA levels, normalized to 18S ribosomal RNA (rRNA), in aorta and MRA in all groups of mice, n=6. *P<0.05 for Sham+Tunica vs Sham, Sham+Tunica+1D11, and Sham+Tunica+SB431542. mechanism and microvascular endothelial function by an oxidative stress-dependent mechanism. These results suggest that inhibition of ER stress could be a useful therapeutic strategy to reverse vascular complications and cardiac damage in hypertension.
Vascular pathology and cardiac damage are well characterized in hypertensive animal models and patients. [18] [19] [20] Several mechanisms have been proposed, such as dysregulation of the renin angiotensin system, 21, 22 endothelin-1, 23,24 cyclooxygenase activity, 25, 26 oxidative stress, 27,28 calcium channels, 29 immune function, 17, 30 and inflammation. 31 Previous studies established the relationship among ER stress, diabetes mellitus, obesity, and cardiovascular diseases, [32] [33] [34] [35] [36] but the mechanism and the significance of ER stress in hypertension-induced vascular dysfunction and cardiac damage are still unknown.
The chemical chaperone PBA and endogenous bile acids such as Tudca are known to modulate ER function, stabilize protein conformation, improve ER folding capacity, and facilitate mutant proteins trafficking. 31, 37 It is well established that increased arterial blood pressure is associated with cardiovascular complications, such as cardiac hypertrophy and fibrosis, renal failure, and vascular endothelial dysfunction. In the present study, we demonstrated that ang II-induced hypertension and increased blood glucose level were reduced after ER stress inhibition, indicating that ER stress is an important factor in the development of hypertension and prediabetic state. It is not surprising that the blood glucose level increased after ang II infusion because it is reported that ang II stimulates the degradation of insulin receptor substrate 1. 38 In addition, it has been shown that ER stress inhibition has a beneficial effect in type 1 and type 2 diabetes mellitus in terms of glucose regulation. 31, 39 These results explain the relationship among hypertension, prediabetic stage, and ER stress.
Cardiac hypertrophy and fibrosis are well documented in hypertensive animals and patients. 40, 41 Hypertensioninduced cardiac hypertrophy is a progressive event associated with myocardial remodeling characterized by fibrosis and alterations in cardiomyocytes size and function. 42 In our model, ang II-induced cardiac hypertrophy and fibrosis were associated with ER stress induction. Interestingly, ER Figure 6 . A and D, Endothelium-dependent relaxation in response to acetylcholine (Ach) in aorta and mesenteric resistance arteries (MRA) from mice treated with or without Tunica with and without 1D11 or SB431542 in aorta and MRA, n=5. *P<0.05 for Sham+Tunica vs Sham, Sham+Tunica+1D11, and Sham+Tunica+SB431542. B and E, Endothelium-dependent relaxation in response to ACh in aorta and MRA from mice treated with Tunica with and without apocynin (Apo), L-NAME, and SB431542 in aorta and MRA, n=5. $P<0.05 for Sham+Tunica+L-NAME and Sham+Tunica+SB431542+L-NAME vs Sham+Tunica+Apo and Sham+Tunica+Apo+SB431542. C and F, Endothelium-dependent relaxation in response to ACh in aorta and MRA from mice treated with Tunica with and without Apo, L-NAME, and 1D11 in aorta and MRA, n=5. #P<0.05 for Sham+Tunica+L-NAME and Sham+Tunica+1D11+L-NAME vs Sham+Tunica+Apo and Sham+Tunica+Apo+1D11.
stress inhibition blunted ang II-induced cardiac hypertrophy and fibrosis suggesting that ER stress is an important factor in the development of cardiac damage in hypertension. Cardiac fibrosis is a result of the pathological accumulation of extracellular matrix components, particularly collagens I and II. 43 Importantly, our data indicate that the increased collagen I expression in hypertensive mice hearts was reduced after ER stress inhibition. It is well known that in hypertension, TGF-β1 stimulates collagen synthesis. 44 Our data showed that active TGF-β1 and its downstream signaling Smad2/3 were increased in mice infused with ang II and were reduced after ER stress inhibition. In addition, we observed an increase in the size of cardiomyocytes, which was reduced after ER stress inhibition. The loss of cardiomyocytes by apoptosis has emerged as an important mechanism contributing to myocardial remodeling in response to hemodynamic overload. 45, 46 Our data indicate that cardiomyocyte apoptosis was increased in hypertensive mice compared with Sham and hypertensive mice treated with ER stress inhibitors.
It is well known that hypertension is associated with vascular endothelial dysfunction. 47, 48 However, the role of ER stress in vascular endothelial dysfunction in hypertension is still unknown. Ang II-induced hypertension reduced EDR and eNOS phosphorylation and enhanced ER stress in aorta and MRA. Importantly, ER stress inhibition improved EDR in aorta and MRA, and this was associated with an increase in eNOS phosphorylation.
TGF-β1 and oxidative stress have been proposed as important factors in the development of vascular complications in hypertension [49] [50] [51] and cardiovascular disease. 52 In our model, ang II-induced hypertension enhances TGF-β1 activity and oxidative stress levels in aorta whereas only oxidative stress was increased in MRA. Interestingly, ER stress inhibition reduced oxidative stress levels in aorta and MRA, and this was associated with enhanced EDR. Similarly, the enhanced TGF-β1 activity was reduced in aorta after ER stress inhibition. Our data were supported by the reduction in Smad2/3 phosphorylation. Our findings suggest that oxidative stress and TGF-β1 are downstream signaling mechanisms of ER stress and are in agreement with previous studies reporting that ER stress induction increases reactive oxygen species. 53 In addition, studies using cell cultures demonstrated that oxidative stress can also increase ER stress suggesting the possibility that ER stress and oxidative stress can activate each other. 54, 55 Ang II-induced hypertension induces ER stress, which enhances TGF-β1 activity and oxidative stress in aorta and MRA, respectively. TGF-β1 is a profibrotic factor involved in vascular and cardiac structural remodeling in a variety of cardiovascular diseases. The inhibition of ER stress reduced TGF-β1 activity in aorta and restored EDR. In addition, TGF-β1 inhibition improved EDR in aorta from mice infused with ER stress inducer (tunycamycin), but no effect was observed in MRA. These in vivo results were supported by in vitro studies in which the acute inhibition of the TGF-β1 activity improves EDR in aorta in the presence of ER stress. Further studies are needed to delineate the mechanism linking ER stress to the TGF-β1 pathway and EDR. The inhibition of TGF-β1 pathway did not affect EDR in MRA, indicating that TGF-β1 is most likely an important factor in large arteries than resistance arteries EDR in ang II-induced hypertension.
Our study demonstrates for the first time the importance of ER stress in the regulation of arterial blood pressure and cardiac damage, and elucidates a differential effect in macro-and microvascular function, TGF-β1, and oxidative stress-dependent mechanisms, respectively. The present study suggests that ER stress could be a potential target for a novel therapeutic strategy to reverse hypertension-induced vascular and cardiac damage.
